Riyad Al‐Lehebi
A5005737760- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Delphi Technique in Research
- Eosinophilic Esophagitis
- Allergic Rhinitis and Sensitization
- IL-33, ST2, and ILC Pathways
- Obstructive Sleep Apnea Research
- Eosinophilic Disorders and Syndromes
- Bariatric Surgery and Outcomes
- Cardiovascular Disease and Adiposity
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Pharmaceutical studies and practices
- Long-Term Effects of COVID-19
- Innovations in Medical Education
- Musculoskeletal Disorders and Rehabilitation
- Congenital Diaphragmatic Hernia Studies
- Medical Imaging and Pathology Studies
- Soft tissue tumor case studies
- COVID-19 Clinical Research Studies
- Diversity and Career in Medicine
- Autoimmune and Inflammatory Disorders Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Alfaisal University
2022-2025
King Fahd Medical City
2019-2025
Royal Victoria Hospital
2023
Lund University
2023
Rashid Hospital
2023
Hospital de Cruces
2023
Skåne University Hospital
2023
University of Ulster
2023
Dubai Health Authority
2023
Umm al-Qura University
2006
Rationale: There is no consensus on criteria to include in an asthma remission definition real-life. Factors associated with achieving post-biologic-initiation remain poorly understood. Objectives: To quantify the proportion of adults severe multi-domain-defined and identify pre-biologic characteristics which may be used predict it. Methods: This was a longitudinal cohort study using data from 23 countries International Severe Asthma Registry. Four outcome domains were assessed 1-year pre-...
The International Severe Asthma Registry (ISAR) was established in 2017 to advance the understanding of severe asthma and its management, thereby improving patient care worldwide. As first global registry for adults with asthma, ISAR enabled individual registries standardize pool their data, creating a comprehensive, harmonized dataset sufficient statistical power address key research questions knowledge gaps. Today, is largest repository real-world data on curating nearly 35,000 patients...
BackgroundInvestigation for the presence of asthma comorbidities is recommended by GINA as their can complicate management.ObjectiveTo understand prevalence and pattern multimorbidity in adults with severe association asthma-related outcomes.MethodsThis was a cross-sectional study using data from International Severe Asthma Registry 22 countries. Thirty were identified categorized priori either (1) potentially T2-related, (2) oral corticosteroid (OCS)-related or (3) mimicking/aggravating...
Previous studies investigating the impact of comorbidities on effectiveness biologic agents have been relatively small and short duration not compared classes agents.
Background To date, studies investigating the association between pre-biologic biomarker levels and post-biologic outcomes have been limited to single biomarkers assessment of biologic efficacy from structured clinical trials. Aim elucidate associations individual or their combinations with pre-to-post changes in asthma real-life. Methods This was a registry-based, cohort study using data 23 countries, which shared International Severe Asthma Registry (May 2017-February 2023). The...
BACKGROUND Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS), nor compared to effectiveness continuing HOCS alone. OBJECTIVE To examine the initiating a large, real-world cohort adult severe asthma and HOCS. METHODS This was propensity-score-matched, prospective study using data from International Severe Asthma Registry (http://isaregistries.org/). Between January 2015 February 2021, (long-term OCS ≥1 year or ≥4 courses rescue...
Patients with severe asthma may present characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile adult patients both anti-IgE and anti-IL5/5R compare effectiveness classes treatment in real life.This a prospective cohort study that included from 22 countries enrolled into International Severe Asthma registry (ISAR) who were anti-IL5/5R. The compared 1:1 matched cohort. Exacerbation rate primary...
What is already known about the topic? Response to biologics variable, partly due inclusion of different outcomes in response definitions (e.g. exacerbations, long-term corticosteroid dose, symptom control, lung function). Identifying those most likely respond real-life has proven challenging. does this article add our knowledge? and their predictors vary according outcome assessed. A greater pre-biologic impairment associated with better for all However shorter asthma duration function...
Asthma morbidity and health-care utilization are known to exhibit a steep socioeconomic gradient. Further investigation into the modulators of this effect is required identify potentially modifiable factors.We identified cohort patients with asthma from Optimum Patient Care Research Database (OPCRD). We compared demographics, clinical variables, by quintile UK 2011 Indices Multiple Deprivation based on location patients' general practice. Multivariable analyses were conducted using...
Objective:Severe asthma burdens patients and presents clinical management challenges for healthcare professionals. Biologics are crucial interventions severe type two (T2) with high eosinophil counts. We conducted a Delphi consensus in seven developing or typically underrepresented countries to understand expert agreement on managing inflammation.
Biological therapies have revolutionized the approach to treating asthma. This retrospective study evaluates biologics impact on asthma outcomes, clinical remission, adherence prevalence, and influence of outcomes. Baseline characteristics post-therapy changes were analysed, was measured using percentage days covered with therapy (PDC%). A total 67 patients initiated included. Clinical improvements statistically significant outcomes observed across all biologics, including reduced attacks, a...
Asthma management is strongly dependent on physician and patient beliefs perceptions about the disease its long-term treatment. The APPaRENT 3 study was conducted to explore factors influencing treatment choice understand patients' physicians' attitudes perspectives use of controller inhalers in regular versus flexible dosing for asthma management. This cross-sectional survey patients with treating physicians seven countries: Indonesia, Malaysia, Philippines, Thailand, Vietnam (patient...
The Nucala Effectiveness Study (NEST) assessed the effectiveness of mepolizumab in patients with severe asthma (SA) countries previously underrepresented real-world studies. A multi-country, bi-directional, self-controlled, observational cohort study conducted Colombia, Chile, India, Türkiye, Saudi Arabia, United Arab Emirates, Kuwait, Oman, and Qatar. Historical and/or prospective data from SA were 12 months pre- post-mepolizumab initiation. Primary endpoint: incident rate ratio (IRR)...
Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of HOCS who did and biologics.Baseline (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses steroid bursts in a year) from International Severe Asthma Registry (ISAR; https://isaregistries.org/), initiated (anti-lgE, anti-IL5/5R anti-IL4R), were described time biologic initiation registry enrolment....
Standardised data collection has enabled individual severe asthma registries to collect unified and increase statistical power for research irrespective of ISAR affiliations.